{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:41:36Z","timestamp":1760784096112},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T00:00:00Z","timestamp":1452556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0145705","type":"journal-article","created":{"date-parts":[[2016,1,12]],"date-time":"2016-01-12T19:12:18Z","timestamp":1452625938000},"page":"e0145705","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation"],"prefix":"10.1371","volume":"11","author":[{"given":"Gregory D.","family":"Ferguson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronique","family":"Plantevin-Krenitsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Jensen-Pergakes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. J.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanaa","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Celeridad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelven","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Nadolny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lida","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrick","family":"Packard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbra","family":"Pagarigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason","family":"Haelewyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trish","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Hickman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans","family":"Baculi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Miyazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilgrim","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Chamberlain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"LeBrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weilin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brydon","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Blease","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,1,12]]},"reference":[{"key":"ref1","first-page":"159","article-title":"The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens","volume":"106","author":"K Egerer","year":"2009","journal-title":"Deutsches Arzteblatt International"},{"key":"ref2","first-page":"23","article-title":"Auto-antibodies and autoreactive T-cells in rheumatoid arthritis: pathogenetic players and diagnostic tools. Clinical Reviews in Allergy &amp;","volume":"32","author":"G Steiner","year":"2007","journal-title":"Immunology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1186\/ar1847","article-title":"Analysis of Fcgamma receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B","volume":"8","author":"AW Morgan","year":"2006","journal-title":"Arthritis Research & Therapy"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q","article-title":"Involvement of Fcgamma receptor IIIA genotypes in susceptibility to rheumatoid arthritis","volume":"43","author":"A Nieto","year":"2000","journal-title":"Arthritis and Rheumatism"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving concepts of rheumatoid arthritis","volume":"423","author":"GS Firestein","year":"2003","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to centre stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"JL Browning","year":"2006","journal-title":"Nature Reviews Drug Discovery"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1517\/13543784.13.7.743","article-title":"Targeting Syk as a treatment for allergic and autoimmune disorders","volume":"13","author":"BR Wong","year":"2004","journal-title":"Expert Opinion on Investigational Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1128\/MCB.18.7.4209","article-title":"The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils","volume":"18","author":"F Kiefer","year":"1998","journal-title":"Mol Cell Biol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1084\/jem.182.6.1815","article-title":"Role of the Syk autophosphorylation site and SH2 domains in B cell antigen receptor signaling","volume":"182","author":"T Kurosaki","year":"1995","journal-title":"J Exp Med"},{"key":"ref10","first-page":"2595","article-title":"Critical role for the tyrosine kinase Syk in signalling through the high affinity IgE receptor of mast cells","volume":"13","author":"PS Costello","year":"1996","journal-title":"Oncogene"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/378303a0","article-title":"Syk tyrosine kinase required for mouse viability and B-cell development","volume":"378","author":"AM Cheng","year":"1995","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/intimm\/dxs078","article-title":"Syk-dependent signaling pathways in neutrophils and macrophages are indispensable in the pathogenesis of anti-collagen antibody-induced arthritis","volume":"24","author":"N Ozaki","year":"2012","journal-title":"International Immunology"},{"issue":"7","key":"ref13","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/art.27438","article-title":"Genetic deficiency of Syk protects mice from autoantibody-induced arthritis","volume":"62","author":"Z Jakus","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"8","key":"ref14","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.4049\/jimmunol.1100341","article-title":"Deletion of Syk in neutrophils prevents immune complex arthritis","volume":"187","author":"ER Elliott","year":"2010","journal-title":"J Immunol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1124\/jpet.106.109058","article-title":"R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation","volume":"319","author":"S Braselmann","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.clim.2007.03.543","article-title":"Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor","volume":"124","author":"PR Pine","year":"2007","journal-title":"Clinical Immunology"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1124\/jpet.111.188441","article-title":"Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis","volume":"340","author":"G Coffey","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1021\/jm201271b","article-title":"Discovery and development of spleen tyrosine kinase (SYK) inhibitors","volume":"55","author":"R Singh","year":"2012","journal-title":"Journal of Medicinal Chemistry"},{"key":"ref19","unstructured":"AstraZeneca (2013) AstraZeneca announces top-line results from Phase III OSKIRA Trials of FOSTAMATINIB and decision not to proceed with regulatory filings. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.astrazeneca.com:\" xlink:type=\"simple\">http:\/\/www.astrazeneca.com:<\/ext-link> 06-04-2013"},{"key":"ref20","unstructured":"National Institutes of Health (2014) BIIB057 in Subjects With Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs (EMBRACE). <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov:\" xlink:type=\"simple\">http:\/\/www.clinicaltrials.gov:<\/ext-link> 11-01-2014"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1073\/pnas.0511292103","article-title":"An efficient rapid system for profiling the cellular activities of molecular libraries","volume":"103","author":"JS Melnick","year":"2006","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0145-2126(02)00343-0","article-title":"Characterization of novel stem cell factor responsive human mast cell lines LAD 1 and 2 established from a patient with mast cell sarcoma\/leukemia; activation following aggregation of FcepsilonRI or FcgammaRI","volume":"27","author":"AS Kirshenbaum","year":"2003","journal-title":"Leukemia Research"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/oxfordjournals.jbchem.a022233","article-title":"Establishment and characterization of a novel human rheumatoid fibroblast-like synoviocyte line, MH7A, immortalized with SV40 T antigen","volume":"124","author":"K Miyazawa","year":"1998","journal-title":"Journal of Biochemistry"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1107\/S0108767303005488","article-title":"Multiparametric scaling of diffraction intensities","volume":"59","author":"Z Otwinowski","year":"2003","journal-title":"Acta crystallographica Section A, Foundations of Crystallography"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1107\/S0907444996012255","article-title":"Refinement of macromolecular structures by the maximum-likelihood method","volume":"53","author":"GN Murshudov","year":"1997","journal-title":"Acta crystallographica Section D, Biological Crystallography"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1177\/1087057104269731","article-title":"Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes","volume":"10","author":"OV Trubetskoy","year":"2005","journal-title":"Journal of Biomolecular Screening"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/cyto.990110402","article-title":"Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry","volume":"11","author":"MR Loken","year":"1990","journal-title":"Cytometry"},{"issue":"23","key":"ref28","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1021\/jm070562u","article-title":"Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases","volume":"50","author":"PP Graczyk","year":"2007","journal-title":"J Med Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood.V97.4.1050","article-title":"Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12)","volume":"97","author":"Y Kuno","year":"2001","journal-title":"Blood"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"4936","DOI":"10.1016\/j.bmc.2005.05.033","article-title":"Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives","volume":"13","author":"H Hisamichi","year":"2005","journal-title":"Bioorg & Med Chem"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1182\/blood.V95.7.2312","article-title":"Phenotypic and functional characteristics of hematopoietic cell lineages in CD69-deficient mice","volume":"95","author":"P Lauzurica","year":"2000","journal-title":"Blood"},{"key":"ref32","first-page":"10","article-title":"Use of CD63 expression as marker of in vitro basophil activation in identifying the culprit in insect venom allergy","volume":"14","author":"B Eberlein-Konig","year":"2004","journal-title":"Journal of Investigational Allergology & Clinical Immunology"},{"key":"ref33","first-page":"1396","article-title":"Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway of complement","volume":"20","author":"EC Keystone","year":"1977","journal-title":"Arthritis and Rheumatism"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1046\/j.1365-2567.2001.01270.x","article-title":"Tumour necrosis factor-alpha potentiates CR3-induced respiratory burst by activating p38 MAP kinase in human neutrophils","volume":"103","author":"M Forsberg","year":"2001","journal-title":"Immunology"},{"issue":"7","key":"ref35","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1182\/blood-2005-03-1239","article-title":"Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production","volume":"106","author":"DM Underhill","year":"2005","journal-title":"Blood"},{"issue":"3","key":"ref36","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/j.1432-1033.1997.t01-2-00792.x","article-title":"Interleukin-3 activates Syk in a human myeloblastic leukemia cell line, AML193","volume":"249","author":"M Tsubokawa","year":"1997","journal-title":"European Journal of Biochemistry \/ FEBS"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1124\/jpet.105.097436","article-title":"A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes","volume":"317","author":"HS Cha","year":"2006","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","article-title":"Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis","volume":"233","author":"B Bartok","year":"2010","journal-title":"Immunological Reviews"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/rheumatology\/ket225","article-title":"Inhibition of spleen tyrosine kinase in the treatment of rheumatoid arthritis","volume":"52","author":"JS Nijjar","year":"2013","journal-title":"Rheumatology"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1136\/annrheumdis-2012-203116","article-title":"Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis","volume":"73","author":"E Salgado","year":"2014","journal-title":"Annals of the Rheumatic Diseases"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"MI Davis","year":"2011","journal-title":"Nature Biotechnology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2006.06291.x","article-title":"Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells","volume":"135","author":"VL Grandage","year":"2006","journal-title":"British Journal of Haematology"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"7","author":"DM Meyer","year":"2010","journal-title":"Journal of Inflammation"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1146\/annurev.immunol.19.1.275","article-title":"IgG Fc receptors","volume":"19","author":"JV Ravetch","year":"2001","journal-title":"Annual Review of Immunology"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"R146","DOI":"10.1186\/ar4329","article-title":"Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy","volume":"15","author":"C Liao","year":"2013","journal-title":"Arthritis Research & Therapy"},{"key":"ref46","first-page":"S51","article-title":"Collagen induced arthritis: an experimental model for rheumatoid arthritis with involvement of both DTH and immune complex mediated mechanisms","volume":"3","author":"R Holmdahl","year":"1989","journal-title":"Clinical and Experimental Rheumatology Suppl"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1186\/1471-2164-13-710","article-title":"The arthritis severity locus Cia5a regulates the expression of inflammatory mediators including Syk pathway genes and proteases in pristane-induced arthritis","volume":"13","author":"M Brenner","year":"2012","journal-title":"BMC Genomics"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"8145","DOI":"10.4049\/jimmunol.181.11.8145","article-title":"Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells","volume":"181","author":"S Krishnan","year":"2008","journal-title":"Journal of Immunology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"e74550","DOI":"10.1371\/journal.pone.0074550","article-title":"Spleen tyrosine kinase (Syk) regulates systemic lupus erythematosus (SLE) T cell signaling","volume":"8","author":"AP Grammatikos","year":"2013","journal-title":"PLOS One"},{"issue":"16","key":"ref50","doi-asserted-by":"crossref","first-page":"6158","DOI":"10.1073\/pnas.0401602101","article-title":"The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase","volume":"101","author":"A Mocsai","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12048","article-title":"Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies","volume":"76","author":"M Baluom","year":"2013","journal-title":"British Journal of Clinical Pharmacology"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1111\/bph.12559","article-title":"The Contribution of Vegf Signalling to Fostamatinib-Induced Blood Pressure Elevation","volume":"171","author":"M Skinner","year":"2014","journal-title":"British Journal of Pharmacology"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.taap.2007.03.027","article-title":"Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406","volume":"221","author":"Y Zhu","year":"2007","journal-title":"Toxicology and Applied Pharmacology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.4049\/jimmunol.0902819","article-title":"Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050","volume":"184","author":"JS Fridman","year":"2010","journal-title":"Journal of Immunology"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"A Quintas-Cardama","year":"2010","journal-title":"Blood"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1038\/jidsymp.2013.29","article-title":"Janus kinases: an ideal target for the treatment of autoimmune diseases","volume":"16","author":"M Gadina","year":"2013","journal-title":"Journal of Investigative Dermatology Symposium Proceedings"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1359-6101(01)00030-2","article-title":"Thrombopoietin: a pan-hematopoietic cytokine. Cytokine &amp;","volume":"13","author":"AE Geddis","year":"2002","journal-title":"Growth Factor Reviews"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1182\/blood-2008-07-166439","article-title":"Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk","volume":"113","author":"A Podolanczuk","year":"2009","journal-title":"Blood"},{"key":"ref59","unstructured":"Rigel Pharmaceuticals (2013) Rigel Provides Pipeline Update. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ir.rigel.com:\" xlink:type=\"simple\">http:\/\/ir.rigel.com:<\/ext-link> 10-24-2013."},{"key":"ref60","unstructured":"Genetic Engineering and Biotechnology News. Rigel Scuttles R333 after Phase II Flop. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.genengnews.com\/gen-news-highlights\/rigel-scuttles-r333-after-phase-ii-flop\/81249024:\" xlink:type=\"simple\">http:\/\/www.genengnews.com\/gen-news-highlights\/rigel-scuttles-r333-after-phase-ii-flop\/81249024:<\/ext-link> 10-25-2013."},{"key":"ref61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/13543784.2011.570329","article-title":"The Syk kinase as a therapeutic target in leukemia and lymphoma","volume":"20","author":"DG Efremov","year":"2011","journal-title":"Expert Opinion on Investigational Drugs"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0145705","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T19:33:25Z","timestamp":1718307205000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0145705"}},"subtitle":[],"editor":[{"given":"Emilio","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,1,12]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,1,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0145705","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,1,12]]}}}